Rationale and patient selection for interventional therapies in Parkinson’s disease

References

• World Health Organization. Global health and ageing. 2011.
   Google Scholar
• Birkmayer W, Hornykiewicz O. The effect of l-3, 4-dihydroxyphenylalanine (= DOPA) on akinesia in parkinsonism. Parkinsonism Relat Disord. 1998;4:59–60.
   PubMedGoogle Scholar
• Marsden C, Parkes J. Success and problems of long-term levodopa therapy in Parkinson’s disease. The Lancet. 1977;309(8007):345–349.
   Google Scholar
• Ahlskog JE, Muenter MD. Frequency of levodopa‐related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001;16(4):698–704.
   Google Scholar
• Ngoga D, Mitchell R, Kausar J, et al. Deep brain stimulation improves survival in severe Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2014;85(1):17–22.
   PubMed Web of Science ®Google Scholar
• Follett KA, Weaver FM, Stern M, et al. Pallidal versus subthalamic deep-brain stimulation for Parkinson’s disease. N Engl J Med. 2010;362(22):2077–2091.
   PubMed Web of Science ®Google Scholar
• Volkmann J, Allert N, Voges J. Long-term results of bilateral pallidal stimulation in Parkinson’s disease. Ann Neurol. 2004;55:65–71.
   Web of Science ®Google Scholar
• Williams A, Gill S, Varma T, et al. Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson’s disease (PD SURG trial): a randomised, open-label trial. Lancet Neurol. 2010;9(6):581–591.
   Web of Science ®Google Scholar
• Giugni JC, Okun MS. Treatment of advanced Parkinson’s disease. Curr Opin Neurol. 2014;27(4):450–460.
   PubMed Web of Science ®Google Scholar
• Krack P, Fraix V, Mendes A, et al. Postoperative management of subthalamic nucleus stimulation for Parkinson’s disease. Mov Disord. 2002;17:S188–S97.
   PubMedGoogle Scholar
• Abboud H, Mehanna R, Machado A, et al. Comprehensive, multidisciplinary deep brain stimulation screening for Parkinson patients: no room for “short cuts”. Move Disord Clin Pract. 2014;1:336–341.
   PubMedGoogle Scholar
• Mehanna R, Lai EC. Deep brain stimulation in Parkinson’s disease. Transl Neurodegener. 2013;2(22).
   PubMedGoogle Scholar
• Okun MS, Fernandez HH, Rodriguez RL, et al. Identifying candidates for deep brain stimulation in Parkinson’s disease. Geriatrics. 2007;62:18–24.
   PubMedGoogle Scholar
• DeLong MR, Huang KT, Gallis J, et al. Effect of advancing age on outcomes of deep brain stimulation for Parkinson disease. JAMA Neurol. 2014;71:1290–1295.
   PubMedGoogle Scholar
• Neurology Awareness and Research Foundation. 1st ever DBS surgery of a 9 yr old boy with Parkinson”s disease, Alhamdullilah! (2018, June 14)
   Google Scholar
• Voges J, Waerzeggers Y, Maarouf M, et al. Deep-brain stimulation: long-term analysis of complications caused by hardware and surgery—experiences from a single centre. J Neurol Neurosurg Psychiatry. 2006;77:868–872.
   PubMedGoogle Scholar
• Fenoy AJ, Simpson JRK. Management of device-related wound complications in deep brain stimulation surgery: clinical article. J Neurosurg. 2012;116:1324–1332.
   PubMedGoogle Scholar
• Zrinzo L, Foltynie T, Limousin P, et al. Reducing hemorrhagic complications in functional neurosurgery: a large case series and systematic literature review: clinical article. J Neurosurg. 2012;116:84–94.
   PubMedGoogle Scholar
• Coley E, Farhadi R, Lewis S, et al. The incidence of seizures following deep brain stimulating electrode implantation for movement disorders, pain and psychiatric conditions. Br J Neurosurg. 2009;23(2):179–183.
   PubMed Web of Science ®Google Scholar
• Follett KA, Weaver FM, Stern M, et al. Pallidal versus subthalamic deep-brain stimulation for Parkinson’s disease. N Engl J Med. 2010;362(2077–91).
   PubMedGoogle Scholar
• Voon V, Krack P, Lang AE, et al. A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson’s disease. Brain. 2008;131(10):2720–2728.
   PubMedGoogle Scholar
• Okun MS, Tagliati M, Pourfar M, et al. Management of referred deep brain stimulation failures: a retrospective analysis from 2 movement disorders centers. Arch Neurol. 2005;62:1250–1255.
   PubMed Web of Science ®Google Scholar
• Ellis T-M, Foote KD, Fernandez HH, et al. Reoperation for suboptimal outcomes after deep brain stimulation surgery. Neurosurgery. 2008;63(2):256–64; discussion 264–5.
   PubMedGoogle Scholar
• Nyholm D, Remahl AN, Dizdar N, et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology. 2005;64(2):216–223.
   PubMed Web of Science ®Google Scholar
• Nilsson D, Hansson LE, Johansson K, et al. Long‐term intraduodenal infusion of a water based levodopa‐carbidopa dispersion in very advanced Parkinson’s disease. Acta Neurol Scand. 1998;97:175–183.
   PubMedGoogle Scholar
• Fernandez HH, Odin P. Levodopa-carbidopa intestinal gel for treatment of advanced Parkinson’s disease. Curr Med Res Opin. 2011;27(5):907–919.
   PubMed Web of Science ®Google Scholar
• Fernandez HH, Standaert DG, Hauser RA, et al. Levodopa‐carbidopa intestinal gel in advanced Parkinson’s disease: final 12‐month, open‐label results. Mov Disord. 2015;30:500–509.
   PubMed Web of Science ®Google Scholar
• Fernandez HH, Vanagunas A, Odin P, et al. Levodopa–carbidopa intestinal gel in advanced Parkinson’s disease open-label study: interim results. Parkinsonism Relat Disord. 2013;19(3):339–345.
   Web of Science ®Google Scholar
• Slevin JT, Fernandez HH, Zadikoff C, et al. Long-term safety and maintenance of efficacy of levodopa-carbidopa intestinal gel: an open-label extension of the double-blind pivotal study in advanced Parkinson’s disease patients. J Parkinsons Dis. 2015;5:165–174.
   PubMedGoogle Scholar
• Olanow CW, Kieburtz K, Odin P, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014;13(2):141–149.
   Web of Science ®Google Scholar
• Zibetti M, Merola A, Artusi C, et al. Levodopa/carbidopa intestinal gel infusion in advanced Parkinson’s disease: a 7‐year experience. Eur J Neurol. 2014;21:312–318.
   PubMed Web of Science ®Google Scholar
• Cossu G, Ricchi V, Pilleri M, et al. Levodopa–carbidopa intrajejunal gel in advanced Parkinson disease with “on” freezing of gait. Neurol Sci. 2015;36:1683–1686.
   PubMed Web of Science ®Google Scholar
• Fernandez H, Odin P. Levodopa–carbidopa intestinal gel for treatment of advanced Parkinson’s disease. Curr Med Res Opin. 2011;27(5):907–919.
   PubMed Web of Science ®Google Scholar
• Galazky I, Schoof J, Stallforth S, et al. Guillain–barre/CIDP-like neuropathy in two parkinsonian patients following intestinal levodopa/carbidopa treatment. Parkinsonism Relat Disord. 2014;20(1):125–127.
   PubMed Web of Science ®Google Scholar
• Antonini A, Mancini F, Canesi M, et al. Duodenal levodopa infusion improves quality of life in advanced Parkinson’s disease. Neurodegenerative Dis. 2008;5(5):268–276.
   PubMedGoogle Scholar
• Sensi M, Cossu G, Mancini F, et al. Which patients discontinue? Issues on Levodopa/carbidopa intestinal gel treatment: Italian multicentre survey of 905 patients with long-term follow-up. Parkinsonism Relat Disord. 2017;38:90–92.
   PubMed Web of Science ®Google Scholar
• Puente V, De Fabregues O, Oliveras C, et al. Eighteen month study of continuous intraduodenal levodopa infusion in patients with advanced Parkinson’s disease: impact on control of fluctuations and quality of life. Parkinsonism Relat Disord. 2010;16(2):139–141.
   PubMedGoogle Scholar
• Nyholm D. Duodopa® treatment for advanced Parkinson’s disease: a review of efficacy and safety. Parkinsonism Relat Disord. 2012;18(8):916–929.
   Web of Science ®Google Scholar
• Zorko N, Kojovic M, Flisar D, et al. Suicide in Parkinson’s disease patients treated with levodopa‐carbidopa intestinal gel. Mov Disord. 2015;30(10):1434–1435.
   PubMed Web of Science ®Google Scholar
• Fernandez HH, Standaert DG, Chatamra K, et al. Reply to letter: suicide in Parkinson’s disease patients treated with levodopa‐carbidopa intestinal gel. Mov Disord. 2015;30(10):1435–1436.
   Web of Science ®Google Scholar
• Schwab R, Amador L, Lettvin J. Apomorphine in Parkinson’s disease. Trans Am Neurol Assoc. 1950;56:251–253.
   Google Scholar
• Frankel JP, Lees AJ, Kempster PA, et al. Subcutaneous apomorphine in the treatment of Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1990;53(2):96–101.
   Web of Science ®Google Scholar
• Deleu D, Hanssens Y, Northway M. Subcutaneous apomorphine—an evidence-based review of its use in Parkinson’s disease. QNRS Repository. 2011;(2011)(64).
   Google Scholar
• LeWitt PA. Subcutaneously administered apomorphine Pharmacokinetics and metabolism. Neurology. 2004;62:S8–S11.
   PubMed Web of Science ®Google Scholar
• Trenkwalder C, Chaudhuri KR, Garcia Ruiz PJ, et al. Expert consensus group report on the use of apomorphine in the treatment of Parkinson’s disease–clinical practice recommendations. Parkinsonism Relat Disord. 2015;21:1023–1030.
   PubMed Web of Science ®Google Scholar
• Garcia Ruiz PJ, Á SI, Ares Pensado B, et al. Efficacy of longterm continuous subcutaneous apomorphine infusion in advanced Parkinson’s disease with motor fluctuations: a multicenter study. Mov Disord. 2008;23(8):1130–1136.
   Web of Science ®Google Scholar
• Katzenschlager R, Hughes A, Evans A, et al. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson’s disease: a prospective study using single-dose challenges. Mov Disord. 2005;20(2):151–157.
   PubMed Web of Science ®Google Scholar
• Stocchi F. Use of apomorphine in Parkinson’s disease. Neurol Sci. 2008;29(Suppl 5):S383–6.
   PubMedGoogle Scholar
• Klostermann F, Jugel C, Marzinzik F. Jejunal levodopa infusion in long‐term DBS patients with Parkinson’s disease. Mov Disord. 2011;26:2298–2299.
   PubMedGoogle Scholar
• Regidor I, Benita V, Mdá DP, et al. Duodenal levodopa infusion for long-term deep brain stimulation–refractory symptoms in advanced Parkinson disease. Clin Neuropharmacol. 2017;40:103–107.
   PubMed Web of Science ®Google Scholar
• Stacy M, Bowron A, Guttman M, et al. Identification of motor and nonmotor wearing-off in Parkinson’s disease: comparison of a patient questionnaire versus a clinician assessment. Mov Disord. 2005;20(6):726–733.
   Web of Science ®Google Scholar
• Todorova A, Ray Chaudhuri K. Subcutaneous apomorphine and non-motor symptoms in Parkinson’s disease. Parkinsonism Relat Disord. 2013;19:1073–1078.
   PubMed Web of Science ®Google Scholar
• Heaton JP, Morales A, Adams MA, et al. Recovery of erectile function by the oral administration of apomorphine. Urology. 1995;45(2):200–206.
   PubMed Web of Science ®Google Scholar
• Gancher ST, Nutt JG, Woodward WR. Apomorphine infusional therapy in Parkinson’s disease: clinical utility and lack of tolerance. Mov Disord. 1995;10(1):37–43.
   PubMed Web of Science ®Google Scholar
• Lees AJ. Dopamine agonists in Parkinson’s disease: a look at apomorphine. Fundam Clin Pharmacol. 1993;7(3–4):121–128.
   PubMed Web of Science ®Google Scholar
• McGee P. Apomorphine treatment: a nurse’s perspective. Acnr. 2002;2:23–24.
   Google Scholar
• Voon V, Pessiglione M, Brezing C, et al. Mechanisms underlying dopamine-mediated reward bias in compulsive behaviors. Neuron. 2010;65(1):135–142.
   PubMed Web of Science ®Google Scholar
• Zahodne LB, Susatia F, Bowers D, et al. Binge eating in Parkinson’s disease: prevalence, correlates and the contribution of deep brain stimulation. J Neuropsychiatry Clin Neurosci. 2011;23(1):56–62.
   PubMed Web of Science ®Google Scholar
• Voon V, Gao J, Brezing C, et al. Dopamine agonists and risk: impulse control disorders in Parkinson’s; disease. Brain. 2011;134(Pt 4):1077–1088.
   PubMedGoogle Scholar
• Martinez‐Martin P, Reddy P, Katzenschlager R, et al. EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson’s disease. Mov Disord. 2015;30:510–516.
   PubMed Web of Science ®Google Scholar
• Seeman P. Parkinson’s disease treatment may cause impulse-control disorder via dopamine D3 receptors. Synapse. 2015;69:183–189.
   PubMed Web of Science ®Google Scholar
• Todorova A, Samuel M, Brown RG, et al. Infusion therapies and development of impulse control disorders in advanced Parkinson disease: clinical experience after 3 years’ follow-up. Clin Neuropharmacol. 2015;38:132–134.
   PubMed Web of Science ®Google Scholar
• Zahodne LB, Fernandez HH. Pathophysiology and treatment of psychosis in Parkinson’s disease: a review. Drugs Aging. 2008;25(8):665–682.
   PubMed Web of Science ®Google Scholar
• Ellis C, Lemmens G, Parkes JD, et al. Use of apomorphine in parkinsonian patients with neuropsychiatric complications to oral treatment. Parkinsonism Relat Disord. 1997;3(2):103–107.
   PubMedGoogle Scholar
• Alegret M, Valldeoriola F, Martí M, et al. Comparative cognitive effects of bilateral subthalamic stimulation and subcutaneous continuous infusion of apomorphine in Parkinson’s disease. Mov Disord. 2004;19(12):1463–1469.
   PubMed Web of Science ®Google Scholar
• Antonini A, Isaias IU, Rodolfi G, et al. A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation. J Neurol. 2011;258:579–585.
   PubMed Web of Science ®Google Scholar
• De Gaspari D, Siri C, Landi A, et al. Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson’s disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus. J Neurol Neurosurg Psychiatry. 2006;77:450–453.
   PubMed Web of Science ®Google Scholar
• Struhal W, Guger M, Hodl S, et al. Attempted suicide under high dose dopaminergic therapy including apomorphine. Wien Klin Wochenschr. 2012;124(13–14):461–463.
   PubMed Web of Science ®Google Scholar
• Worth PF. When the going gets tough: how to select patients with Parkinson’s disease for advanced therapies. Pract Neurol. 2013;practneurol-2012–000463.
   PubMedGoogle Scholar
• Weaver FM, Follett K, Stern M, et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA. 2009;301:63–73.
   PubMedGoogle Scholar
• Pillon B, Ardouin C, Damier P, et al. Neuropsychological changes between “off” and “on” STN or GPi stimulation in Parkinson’s disease. Neurology. 2000;55:411–418.
   PubMed Web of Science ®Google Scholar
• Witt K, Daniels C, Reiff J, et al. Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson’s disease: a randomised, multicentre study. Lancet Neurol. 2008;7(7):605–614.
   PubMed Web of Science ®Google Scholar
• Dujardin K, Defebvre L, Krystkowiak P, et al. Influence of chronic bilateral stimulation of the subthalamic nucleus on cognitive function in Parkinson’s disease. J Neurol. 2001;248(7):603–611.
   PubMed Web of Science ®Google Scholar
• García Ruiz PJ, Á SI, Ares Pensado B, et al. Efficacy of long‐term continuous subcutaneous apomorphine infusion in advanced Parkinson’s disease with motor fluctuations: a multicenter study. Mov Disord. 2008;23(8):1130–1136.
   Web of Science ®Google Scholar
• Chang FC, Tsui DS, Mahant N, et al. 24 h levodopa–carbidopa intestinal gel may reduce falls and “unresponsive” freezing of gait in Parkinson’s disease. Parkinsonism Relat Disord. 2015;21:317–320.
   PubMed Web of Science ®Google Scholar
• Yin Y, Chang F, Mahant N, et al. 2. Antecollis associated with Parkinson’s disease improved following apomorphine therapy. Clin Neurophysiol. 2016;127:e10–e1.
   PubMedGoogle Scholar
• Anderson VC, Burchiel KJ, Hogarth P, et al. Pallidal vs subthalamic nucleus deep brain stimulation in Parkinson disease. Arch Neurol. 2005;62(4):554.
   Google Scholar
• Pietz K, Hagell P, Odin P. Subcutaneous apomorphine in late stage Parkinson’s disease: a long term follow up. J Neurol Neurosurg Psychiatry. 1998;65(5):709–716.
   PubMed Web of Science ®Google Scholar
• Deleu D, Hanssens Y, Northway MG. Subcutaneous apomorphine. Drugs Aging. 2004;21(11): 687–709.
   PubMed Web of Science ®Google Scholar
• Grace Cannard K, Hacker ML, Molinari A, et al. Recruitment and retention in clinical trials of deep brain stimulation in early-stage Parkinson’s disease: past experiences and future considerations. J Parkinsons Dis. 2018;8:421–428.
   PubMedGoogle Scholar
• Wolters E, Lees AJ, Volkmann J, et al. Managing Parkinson’s disease with continuous dopaminergic stimulation. CNS Spectrums. 2008;13:s1–14.
   Google Scholar